|Ceritinib in ALK-rearranged non–small-cell lung cancer|
AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ...
N Engl j med 370, 1189-1197, 2014
|First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study|
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
|Isolation and retrieval of circulating tumor cells using centrifugal forces|
HW Hou, ME Warkiani, BL Khoo, ZR Li, RA Soo, DSW Tan, WT Lim, J Han, ...
Scientific reports 3 (1), 1-8, 2013
|A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer|
KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ...
Nature medicine 18 (4), 521, 2012
|Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells|
ME Warkiani, G Guan, KB Luan, WC Lee, AAS Bhagat, PK Chaudhuri, ...
Lab on a Chip 14 (1), 128-137, 2014
|Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates|
Y Simoni, E Becht, M Fehlings, CY Loh, SL Koo, KWW Teng, JPS Yeong, ...
Nature 557 (7706), 575-579, 2018
|Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial|
DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ...
The lancet oncology 17 (4), 452-463, 2016
|Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC|
C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ...
Journal of Thoracic Oncology 13 (9), 1248-1268, 2018
|Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency|
Y Simoni, M Fehlings, HN KlÝverpris, N McGovern, SL Koo, CY Loh, ...
Immunity 46 (1), 148-161, 2017
|Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development|
DSW Tan, GV Thomas, MD Garrett, U Banerji, JS De Bono, SB Kaye, ...
The Cancer Journal 15 (5), 406-420, 2009
|Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma|
T Tan, WT Lim, KW Fong, SL Cheah, YL Soong, MK Ang, QS Ng, D Tan, ...
International Journal of Radiation Oncology* Biology* Physics 91 (5), 952-960, 2015
|Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib|
JF Gainor, DSW Tan, T De Pas, BJ Solomon, A Ahmad, C Lazzari, ...
Clinical cancer research 21 (12), 2745-2752, 2015
|The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation–Positive Non–Small cell lung cancer: status in 2016|
DSW Tan, SS Yom, MS Tsao, HI Pass, K Kelly, N Peled, RC Yung, ...
Journal of Thoracic Oncology 11 (7), 946-963, 2016
|An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells|
ME Warkiani, BL Khoo, DSW Tan, AAS Bhagat, WT Lim, YS Yap, SC Lee, ...
Analyst 139 (13), 3245-3255, 2014
|Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes|
A Drilon, ZI Hu, GGY Lai, DSW Tan
Nature Reviews Clinical Oncology 15 (3), 151, 2018
|Novel therapeutic targets on the horizon for lung cancer|
WL Tan, A Jain, A Takano, EW Newell, NG Iyer, WT Lim, EH Tan, W Zhai, ...
The Lancet Oncology 17 (8), e347-e362, 2016
|Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head†…|
NG Iyer, DSW Tan, VKM Tan, W Wang, J Hwang, NC Tan, R Sivanandan, ...
Cancer 121 (10), 1599-1607, 2015
|Cancer genomics: diversity and disparity across ethnicity and geography|
DS Tan, TS Mok, TR Rebbeck
J Clin Oncol 34 (1), 91-101, 2016
|Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window|
SR Boyd, D Tan, C Bunce, A Gittos, MH Neale, JL Hungerford, ...
British Journal of Ophthalmology 86 (4), 448-452, 2002
|Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor†…|
YL Wu, L Zhang, DW Kim, X Liu, DH Lee, JCH Yang, MJ Ahn, ...
Journal of Clinical Oncology 36 (31), 3101-+, 2018